

WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Thursday, February 12, 2004

Updated
Search
2/10/04
158

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
	<i>DB=USPT; PLUR=YES; OP=AND</i>		
<input type="checkbox"/>	L1	campylobact\$.clm. or jejuni.clm. or c-coli.clm. or c-fetus.clm.	199
<input type="checkbox"/>	L2	L1 and (antibod\$ or antiser\$ or immunoglob\$ or polyclonal or poly-clonal or immune or igg or siga or iga or igm or anti-flagella or anti-flagella or anti-flagellin).clm.	44
<input type="checkbox"/>	L3	L2 and (vaccin\$ or protect\$ or prevent\$ or treat\$ or inhibit\$ or decreas\$ or reduc\$).clm.	25
<input type="checkbox"/>	L4	(antibod\$ or antiser\$ or immunoglob\$ or polyclonal or poly-clonal or immune or igg or siga or iga or igm or anti-flagella or anti-flagella or anti-flagellin).ti. and ll	7

END OF SEARCH HISTORY

First Hit Fwd Refs

L3: Entry 1 of 25

File: USPT

Apr 8, 2003

US-PAT-NO: 6544510

DOCUMENT-IDENTIFIER: US 6544510 B2

TITLE: Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications

DATE-ISSUED: April 8, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Olshenitsky; Mark	Natania			IL
Buchman; Genadi	Bat Yam			IL

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
The Bio Balance Corporation	New York	NY			02

APPL-NO: 09/ 986860 [PALM]

DATE FILED: November 13, 2001

PARENT-CASE:

This is a Divisional Application of U.S. application Ser. No. 09/725,846 filed Nov. 30, 2000, which is pending, which is a Continuation-in-Part of PCT Application Ser. No. IL00/00318, filed Jun. 1, 2000.

FOREIGN-APPL-PRIORITY-DATA:

COUNTRY	APPL-NO	APPL-DATE
IL	130303	June 3, 1999

INT-CL: [07] A01 N 63/00, A61 K 35/78, A61 K 35/36, A61 K 39/116, A23 L 1/28

US-CL-ISSUED: 424/93.3; 424/93.48, 424/203.1, 424/543, 424/725, 424/747, 424/755, 424/757, 424/774, 424/775, 424/776, 424/777, 424/778, 424/779, 426/2, 426/61, 426/71

US-CL-CURRENT: 424/93.3; 424/203.1, 424/543, 424/725, 424/747, 424/755, 424/757, 424/774, 424/775, 424/776, 424/777, 424/778, 424/779, 424/93.48, 426/2, 426/61, 426/71

FIELD-OF-SEARCH: 424/93.3, 424/93.48, 424/203.1, 424/725, 424/774, 424/777, 424/779, 424/543, 424/747, 424/755, 424/757, 424/775, 424/776, 424/778, 426/2, 426/61, 426/71

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

Clear

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
<input type="checkbox"/> <u>4839281</u>	June 1989	Gorbach et al.	
<input type="checkbox"/> <u>5019506</u>	May 1991	Daly et al.	
<input type="checkbox"/> <u>5032399</u>	July 1991	Gorbach et al.	
<input type="checkbox"/> <u>5176913</u>	January 1993	Honerlagen et al.	424/195.1
<input type="checkbox"/> <u>5443826</u>	August 1995	Borody	424/93.3
<input type="checkbox"/> <u>5691185</u>	November 1997	Dickely et al.	
<input type="checkbox"/> <u>5733765</u>	March 1998	Mollet et al.	
<input type="checkbox"/> <u>5786184</u>	July 1998	Mollet et al.	
<input type="checkbox"/> <u>5866385</u>	February 1999	Dickely et al.	
<input type="checkbox"/> <u>5876773</u>	March 1999	Hagiwara	426/270
<input type="checkbox"/> <u>5891501</u>	April 1999	McKellip et al.	
<input type="checkbox"/> <u>6187990</u>	February 2001	Runeman et al.	
<input type="checkbox"/> <u>6403082</u>	June 2002	Stiles et al.	
<input type="checkbox"/> <u>2001/0049132</u>	December 2001	Kringelum et al.	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
2717492	September 1995	FR	
1501098	February 1978	GB	
56018565	February 1981	JP	
WO 95/16461	June 1995	WO	
WO 96/37210	November 1996	WO	
WO 99/08532	February 1999	WO	

OTHER PUBLICATIONS

Type 1 pili-mediated adherence of *Escherichia coli* strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells, Boundeau, et al, *Molecular Microbiology* (2001) 39(5), pp. 1272-1284.

Regulation of Type 1 Pili Expression as Exemplified by *Escherichia coli* Strain M17, Chesnokova, et al., *Bulletin of Experimental Biology and Medicine*, No. 4, 2001, Immunology and Microbiology, pp. 977-980.

Characterization of New Plasmids from Methylophilic Bacteria, Brenner, et al, *Antonie van Leeuwenhoek* 60: 1991, pp. 43-48.

Transcriptional Regulation of lux Genes Transferred into *Vibrio harveyi*, Miyamoto, et al., *Journal of Bacteriology*, Apr. 1990, vol. 172, No. 4, pp. 2046-2054.

Intergeneric Conjugal Transfer of *Escherichia coli*/Methylobacterium sp. Shuttle Vector, Holubova, et al. *Folia Microbiol.*, 38(4) 1993, pp. 277-280.

Influence of Certain Inhibitors on the Viability of Protein and Nucleic Acid Synthesis in *Escherichia coli*, Avtushenko et al., *Microbiology*, May-Jun. 1985, vol. 54, No. 3, pp. 319-322.

Lactobacillus plantarum 299v Inhibits *Escherichia coli*-Induced Intestinal Permeability, Mangell, et al., *Digestive Diseases and Sciences*, vol. 47, No. 3, Mar. Mar. 2002, pp. 511-516.

Specific Proliferative and Antibody Responses of Premature Infants to Intestinal Colonization with Nonpathogenic Probiotic E-coli Strain Nissle 1917, Cukrowska, et al., Immunol 55, 2002, pp. 204-209.

A New Biological Agent for Treatment of Shiga Toxigenic *Escherichia coli* Infections and Dysentery in Humans, Nature Medicine, vol. 6, No. 3, Mar. 2000, pp. 265-270.

Probiotic Fermented Food Mixtures: Possible Applications in Clinical Anti-Diarrhoea Usage, Rani et al., Nutrition and Health, 1998, vol. 12, pp. 97-105.

Antagonistic Effect of *Lactobacillus Acidophilus*, *Saccharomyces Boulardii* and *Escherichia coli* Combinationa Against Experimental Infections with *Shigella flexneri flexneri* and *Salmonella Enteritidis* Subsp. Typhimurium in Gnotobiotic Mice, Filho-Lima, et al. Journal of Applied Microbiology 2000, 88, pp. 365-370.

Symposium: Probiotic Bacteria: Implications for Human Health, Rolfe, American Society for Nutritional Sciences, 2000, pp. 396S-402S.

The Effect of Probiotic Bacteria on the Adhesion of Pathogens to Human Intestinal Mucus, Tuomola, et al., Federation of European Microbiological Societies Immunology and Medical Microbiological Societies Immunology and Medical Microbiology, 26, 1999, 1999, pp. 137-142.

Characterization of the Integration Site of *Yersinia High-Pathogenecity* Island in *Escherichia coli*, Schubert, et al., Federation of European Microbiological Societies Societies Letters, 179, 1999, pp. 409-414.

Probiotics and E-coli Infections in Man, Lodinova-Zadnikova et al., National Library Library of Medicine, 1999. vol. 20, Issue 3, Supplement, 5 pages.

Reduction of Carriage of Enterohemorrhagic *Escherichia coli* O157:H7 in Cattle by Inoculation with Probiotic Bateria, Zhao, et al., Journal of Clinical Microbiology, Mar. 1998, vol. 36, No. 3, pp. 641-647.

The Possible Role of Probiotics as Dietary Antimutagens, Renner, et al., Mutation Research, 262, 1991, pp. 239-245.

Induction of the Phage Resistance in the Progeny of an Infected Bacterial Cell, Pererva, Biopolymers and Cell, vol. 15, N1, 1999, pp. 63-66.

Properties of Strains of *Escherichia coli* Isolated from the Faeces of Patients with Ulcertative Colities, Patients with Acute Diarrhoea and Normal Persons, Cooke, Journal of Pathology and Bacteriology, vol. 95, No. 1, Jan. 1968, pp. 101-113.

Ulcertative Colitis and *Escherichia coli* with Adhesive Properties, Burke, et al., Journal Clinical Pathology, 1987, 4, pp. 782-786.

Virulence Properties of *Escherichia coli* Strains Isolated from Patients with Inflammatory Bowel Diseases, Giaffer, et al., GUT, 1992, 33, pp. 646-650.

Probiotics: Towards Demonstrating Efficacy, Mattila-Sandholm et al., Trends in Food Science & Technology, 10, 1999, pp. 393-399.

Recolonization Therapy with Nonadhesive *Escherichia coli* for Treatment of Inflammatory Bowel Disease, McCann, et al., Microbial Pathogenesis and Immune Response, vol. 730, 1994, pp. 243-245.

Oral Administration of a Certain Strain of Live *Escherichia coli* for Intestinal Disorders? Beutin, Infection 23, 1995, No. 1., pp. 51/55-62/188.

Properties of *Escherichia coli* Strains of Serotype O6, Blum et al., Infection, 23, 1995, No. 4, pp. 46/234-48/236.

Microbiologists on the Trail of Polluting Bacteria, Malakoff, Science, vol. 295, Mar. 29, 2002, pp. 2352-2353.

Invasive Ability of an *Escherichia coli* Strain Isolated from the Ileal Mucosa of a Patient with Crohn's Disease, Boudea, et al., Infection and Immunity, Sep. 1999, vol. 67, No. 9, pp. 4499-4509.

Pathologic and Physiologic Interactions of Bacteria with the Gastrointestinal Epithelium .sup.1-3, Lei Lu, et al., Am. J. Clin. Nutr. 2001, 73, (supplement), pp. 11248-11308.

Novigen Document Order #5, 36 articles, May 2, 2002, pp. 1-11.

Characterization of New Plasmids from Methylophilic Bacteria, Brener, et al., Antonie van Leeuwenhoek, 60: 1991, pp. 43-48.

Displacement of *Escherichia coli* O157:H7 from Rumen Medium Containing Prebiotic Sugars, de Vaux, et al., Applied and Environmental Microbiology, Feb. 2002, vol. 68, 68, No. 2, pp. 519-524.

Inhibitory Activity of *Bifidobacterium Longum* HY8001 Against Vero Cytotoxin of

Escherichia coli O157:H7, Kim et al., Journal of Food Protection, vol. 64, No. 11, 2001, pp. 1667-1673.

Effect of Probiotics on Enterocyte Bacterial Translocation in vitro, Mattar et al., Pediatric Surgery Int., 2001, 17, pp. 265-268.

A Dietary Probiotic (*Bifidobacterium lactis* HN019) Reduces the Severity of *Escherichia coli* O157:H7 Infection in Mice, Shu, et al., Med. Microbiol Immunol, 2001, 189, pp. 147-152.

Probiotic Treatment Using *Bifidobacterium lactis* HN019 Reduces Weanling Diarrhea Associated with Rotavirus and *Escherichia coli* Infection in a Piglet Model, Shu, et al., Journal of Pediatric Gastroenterology and Nutrition, 33, pp. 171-177.

In vitro Adherence Properties of *Lactobacillus rhamnosus* DR20 and *Bifidobacterium lactis* DR10 Strains and their Antagonistic Activity Against an Enterotoxigenic *Escherichia coli*, Gopal, et al., International Journal of Food Microbiology, 67, 2001, pp. 207-216.

Antimicrobial Activity of Intraurethrally Administered Probiotic *Lactobacillus casei casei* in a Murine Model of *Escherichia coli* Urinary Tract Infection, Asahara, et al., Antimicrobial Agents and Chemotherapy, Jun. 2001, vol. 45, No. 6, pp. 1751-1760.

Probiotic Activities of *Lactobacillus casei rhamnosus*: in vitro Adherence to Intestinal Cells and Antimicrobial Properties, Forestier, et al., Res. Microbiol. 152, 2001, pp. 167-173.

Lactobacillus plantarum Reduces Infection of Pancreatic Necrosis in Experimental Acute Pancreatitis, Mangiante, et al., Digestive Surgery, 2001, 18, pp. 47-50.

Significance of Fecal Volatile Fatty Acids in Shedding of *Escherichia coli* O157 from from Calves: Experimental Infection and Preliminary Use of a Probiotic Product, Ohya, et al., J. Vet. Med. Sci. 62, 11, 2000, pp. 1151-1155.

A Strain of *Enterococcus faecium* (18C23) Inhibits Adhesion of Enterotoxigenic *Escherichia coli* K88 to Porcine Small Intestine Mucus, Jin et al., Applied and Environmental Microbiology, Oct. 2000, vol. 66, No. 10, pp. 4200-4204.

Evaluation of Probiotic Treatment in a Neonatal Animal Model, Lee et al., Pediatr. Surg. Int. 2000, 16, pp. 237-242.

Expression of *Clostridium thermocellum* Endoglucanase Gene in *Lactobacillus gasseri* and *Lactobacillus johnsonii* and Characterization of the Genetically Modified Probiotic *Lactobacilli*, Soon-Chuo, et al., Current Microbiology, vol. 40, 2000, pp. 257-263.

Probiotic Therapy with *E. coli* for Ulcerative Colitis: Take the Good with the Bad, Binder, et al., Gastroenterology 2000, 118, pp. 630-631.

Immunomodulatory Effects of *Lactobacillus plantarum* Colonizing the Intestine of Gnotobiotic Rats, Herias, et al., Clin. Exp. Immunol 1999, 116, pp. 283-290.

Probiotics Inhibit Enteropathogenic *E. coli* Adherence in vitro by Inducing Intestinal Mucin Gene Expression, Mack, et al., American Physiological Society, 1999, pp. G941-G950.

Monoassociation with *Lactobacillus acidophilus* UFV-H2b20 Stimulates the Immune Defense Mechanisms of Germfree Mice, Neumann, et al., Brazilian Journal of Medical and Biological Research 1998, 31, pp. 1565-1573.

Adhesion of Some Probiotic and Dairy *Lactobacillus* Strains to Caco-2 Cell Cultures, Tuomola, et al., International Journal of Food Microbiology, 41, 1998, pp. 45-51.

Effect of Fermented Milk Intake on Plasmid Transfer and on the Persistence of Transconjugants in the Digestive Tract of Gnotobiotic Mice, Duval-Iflah, et al., Antonie van Leeuwenhoek, 73, 1998, pp. 95-102.

Inhibition of in vitro Growth of Enteropathogens by new *Lactobacillus* Isolates of Human Intestinal Origin, Drago, et al., Federation of European Microbiological Societies Microbiology Letters, 153, 1997, pp. 455-463.

The Effect of *Lactobacillus salivarius* Administration on Coliforms and Enterococci in the Crop and Caeca of Chicken Broilers, Rada, et al., Vet. Med. Czech, 40, 1995, 10, pp. 311-315.

Data on the Effects of the Probiotic "Lacto Sacc", Kovacs-Zomborszky, et al., Acta Veterinaria Hungarica 42, 1, 1994, pp. 3-14.

The Effect of *Lactobacillus* spp. on the Attachment of Enterotoxigenic *Escherichia coli* to Isolated Porcine Enterocytes, Spencer, et al., Journal of Applied

Bacteriology, 1994, 77, pp. 215-220.

Distribution of Pathogen Inhibition in the Lactobacillus Isolates of a Commercial Probiotic Consortium, Chateau, et al., Journal of Applied Bacteriology, 1993, 74, pp. 36-40.

Evaluation of the Effect of 3 Probiotics on Experimental Escherichia coli Enterotoxaemia in Weaned Piglets, Cupere et al., J. Vet. Med. B. 39, 1992, pp. 277-284.

Regulation of the Gut Flora Via Food, Gedek, Zbl. Hyg., 191, 1991, pp. 277-301.

Streptococcus Faecium M74 in Control of Diarrhoea Induced by a Human Enterotoxigenic Escherichia coli Strain in an Infant Rabbit Model, Wadstroem, Zbl., Bakt., Hyg., A 257, 1984, pp. 357-363.

Antibacterial Activity of Strains Used in the Dairy Industry, Warminska-Radyko et al., Med. Fac. Landbouww. Univ. Gent. 65/3b, 2000, pp. 559-562.

Characterization of New Plasmids from Methylophilic Bacteria, Brenner, et al., Antonie van Leeuwenhoek 60, 1991, 43-48.

Transcriptional Regulation of lux Genes Transferred into Vibrio harveyi, Miyamoto, et al., Journal of Bacteriology, Apr. 1990, vol. 172, No. 4, pp. 2046-2054.

Study on Small Intestinal Lumenal and Membrane Flora of 30 Healthy Chinese, Ling jia, et al., Chinese Journal of Internal Medicine, vol. 35, Oct. 1996, No. 10, pp. 686-689.

Nutritive Effects of Bacillus Cereus on the Rearing of Piglets, Gedek et al., Arch. Anim. Nutr., 1993, vol. 44, pp. 215-226.

ART-UNIT: 1651

PRIMARY-EXAMINER: Tate; Christopher R.

ASSISTANT-EXAMINER: Srivastava; Kailash C.

ATTY-AGENT-FIRM: G. E. Ehrlich Ltd.

ABSTRACT:

The present invention discloses: (i) a non-pathogenic probiotic microorganism and its probiotic/therapeutic uses; (ii) a formulation comprising an aqueous solution of a volatile fraction (VF) prepared from the extract of at least one plant derived material and its therapeutic uses; (iii) a process of manufacturing the formulation from the plant derived material; (iv) a probiotic composition comprising the non-pathogenic probiotic microorganism of the invention and/or other probiotic microorganism(s) and the formulation of the invention, and its probiotic/therapeutic probiotic/therapeutic uses; (v) a composition for industrial applications comprising comprising the formulation of the invention and microorganism(s) of industrial applicability; and (vi) industrial processes and apparatuses in which the latter composition is used.

19 Claims, 1 Drawing figures

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 25 of 25 returned.**

-
- ☐ 1. [6544510](#). 13 Nov 01; 08 Apr 03. Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications. Olshenitsky; Mark, et al. 424/93.3; 424/203.1 424/543 424/725 424/747 424/755 424/757 424/774 424/775 424/776 424/777 424/778 424/779 424/93.48 426/2 426/61 426/71. A01N063/00 A61K035/78 A61K035/36 A61K039/116 A23L001/28.
-
- ☐ 2. [6485904](#). 13 May 98; 26 Nov 02. DNA encoding a plasminogen activating protein. Rosey; Everett L., et al. 435/6; 435/252.3 435/320.1 435/325 435/69.3 514/44 536/23.7. C12Q001/68.
-
- ☐ 3. [6440423](#). 02 Aug 99; 27 Aug 02. Mutant enterotoxin effective as a non-toxic oral adjuvant. Clements; John D., et al. 424/236.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/240.1 424/241.1 424/257.1 424/261.1 424/278.1 424/282.1 514/2 530/350 530/820 530/825. A61K039/02 A61K039/108 A61K039/106 A61K045/00 C07K001/00.
-
- ☐ 4. [6413523](#). 23 Feb 95; 02 Jul 02. Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use. Clements; John D. 424/241.1; 424/197.11 424/234.1 424/236.1 424/93.1 424/93.48. A61K039/108 A61K039/02 A61K039/385.
-
- ☐ 5. [6329425](#). 21 Oct 97; 11 Dec 01. Modulation of inflammation related to Columnar epithelia. Madara; James L., et al. 514/530; 514/552 514/559 514/573. A61K031/215 A61K031/19.
-
- ☐ 6. [6309835](#). 27 May 99; 30 Oct 01. Methods for quantitating the efficacy of oral care products. Iyer; Lokanathan M., et al. 435/6; 424/49 435/244 435/252.1 536/24.32. C12Q001/68 C12N001/38 A61K007/16 C07H021/04.
-
- ☐ 7. [6309669](#). 27 Jan 97; 30 Oct 01. Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix. Setterstrom; Jean A., et al. 424/486; 424/422 424/423 424/424 424/425 424/484. A61K009/52 A61K047/30.
-
- ☐ 8. [6277379](#). 29 Sep 99; 21 Aug 01. Use of purified invaplex from gram negative bacteria as a vaccine. Oaks; Edwin V., et al. 424/197.11; 424/193.1 424/203.1 424/234.1 424/241.1 424/249.1 424/252.1 424/258.1 435/975 530/350 536/123.1. A61K039/385.
-
- ☐ 9. [6262029](#). 13 Aug 99; 17 Jul 01. Chemically modified saponins and the use thereof as adjuvants. Press; Jeffery B., et al. 514/26; 424/184.1 424/204.1 424/234.1 514/23 536/18.6 536/5. A61K031/70 A61K039/00 C07H015/24.
-
- ☐ 10. [6245892](#). 29 Sep 99; 12 Jun 01. Invaplex from gram negative bacteria, method of purification and methods of use. Oaks; Edwin V., et al. 530/350; 424/282.1 435/7.2 530/416. C07K014/00 C07K001/00 G01N033/53 A61K045/00.
-
- ☐ 11. [6080725](#). 13 Apr 99; 27 Jun 00. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof. Marciani; Dante J.. 514/26; 424/184.1 514/25 536/4.1 536/5. A61K031/705 A61K039/00.
-

-
- ☐ 12. 6033673. 18 Mar 98; 07 Mar 00. Double mutant enterotoxin for use as an adjuvant. Clements; John D.. 424/236.1; 424/184.1 424/241.1 424/278.1 424/282.1 424/832 424/9.2 514/885. A61K039/02 A61K039/108 A61K045/00 X61K039/00.
-
- ☐ 13. 6020125. 07 Jun 95; 01 Feb 00. Basal body rod protein FlgF of campylobacter. Chan; Voon Loong, et al. 435/6; 435/7.21 435/91.2 514/423 514/44. C12Q001/68.
-
- ☐ 14. 5871731. 10 Dec 96; 16 Feb 99. Oral administration of immunoglobulin preparations for treatment of chronic pain syndrome. Sprotte; Gunter, et al. 424/130.1; 424/135.1 424/184.1 514/2 514/21 530/387.1 530/388.1 530/833. A61K039/395 A61K039/38 A61K038/00 C07K016/00.
-
- ☐ 15. 5695946. 03 May 95; 09 Dec 97. Assay method for detecting presence of bacteria. Benjamin; Thomas L., et al. 435/7.32; 435/261 435/6 435/7.31 435/7.33 435/7.35 435/7.37 435/7.92 435/7.95. G01N033/02 G01N033/538 G01N033/547 G01N033/569.
-
- ☐ 16. 5691151. 07 Oct 94; 25 Nov 97. Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca. Braun; Jonathan, et al. 435/7.2; 435/7.24 435/7.25 435/7.32 435/7.9 435/7.95 435/961 435/965 435/975 436/506 436/508. G01N033/564.
-
- ☐ 17. 5665363. 03 Sep 96; 09 Sep 97. Inoculation of animals with dried, pelleted biological materials. Hansen; Richard D., et al. 424/211.1; 424/203.1 424/229.1 424/234.1. A61K039/155.
-
- ☐ 18. 5491068. 31 Dec 92; 13 Feb 96. Assay method for detecting the presence of bacteria. Benjamin; Thomas L., et al. 435/7.32; 435/261 435/7.31 435/7.33 435/7.35 435/7.37 435/7.92 435/7.95. G01N033/02 G01N033/538 G01N033/547 G01N033/569.
-
- ☐ 19. 5484609. 21 Jan 94; 16 Jan 96. Therapeutic compositions and methods. Ko; Thomas S. Y.. 424/470; 424/474 424/490 424/491 424/497 424/78.01 514/2 514/867 514/885 514/964 514/965. A61K009/26 A61K038/00 A01N037/18.
-
- ☐ 20. 5470958. 16 Sep 94; 28 Nov 95. Antisera against a PEB1 antigen from Campylobacter jejuni. Blaser; Martin J., et al. 530/389.5; 424/164.1 435/252.1 435/7.32 435/822. A61K035/16 A61K039/106.
-
- ☐ 21. 5417986. 10 Apr 92; 23 May 95. Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres. Reid; Robert H., et al. 424/499; 424/422 424/426 424/433 424/444 424/455 424/470 424/486 424/488 424/489 424/491. A61K009/50 A61K009/66 A61K009/26.
-
- ☐ 22. 5200344. 13 Nov 90; 06 Apr 93. Diagnostic testing for Campylobacter jejuni or Campylobacter coli infections using novel antigens. Blaser; Martin J., et al. 435/7.32; 435/29 435/7.92 435/961 435/967 436/547 530/389.5. G01N033/569.
-
- ☐ 23. RE34101. 19 Mar 91; 13 Oct 92. Process for preparation of high molecular weight cell-associated protein of Campylobacter pylori and use for serological detection of Campylobacter pylori infection. Evans; Dolores G., et al. 435/7.32; 435/7.1 435/7.92 435/975 530/350 530/806 530/825. C12Q001/00 G01N033/531 G01N033/569.
-
- ☐ 24. 4882271. 10 Mar 88; 21 Nov 89. Process for preparation of high molecular weight cell-associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection. Evans; Dolores G., et al. 435/7.32; 435/12 435/810 436/501 436/518 436/808 436/811

530/350 530/413. G01N033/53 G01N033/543 C12Q001/58 C07K015/00.

☐ 25. 4789544. 01 Dec 87; 06 Dec 88. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation. Nelson; Ralph, et al. 424/203.1; 424/234.1 424/251.1 424/253.1 424/255.1 424/256.1 424/257.1 424/258.1 424/260.1 424/262.1 424/282.1. A61K039/02 A61K039/10 A61K039/108 A61K039/104.

[Generate Collection](#)[Print](#)

Terms	Documents
L2 and (vaccin\$ or protect\$ or prevent\$ or treat\$ or inhibit\$ or decreas\$ or reduc\$).clm.	25

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

First Hit Fwd Refs

L4: Entry 1 of 7

File: USPT

Apr 22, 2003

US-PAT-NO: 6551599

DOCUMENT-IDENTIFIER: US 6551599 B2

TITLE: Monoclonal antibodies against campylobacter jejuni and campylobacter coli
outer membrane antigens

DATE-ISSUED: April 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mandrell; Robert E.	Sonoma	CA		
Bates; Anna H.	Lafayette	CA		
Brandon; David L.	Berkeley	CA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE	CODE
The United States of America, as represented by the Secretary of Agriculture	Washington DC				06	

APPL-NO: 09/ 810873 [PALM]

DATE FILED: March 16, 2001

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a divisional of pending application Ser. No. 09/277,599 filed Mar. 26, 1999, which is a non-provisional of provisional application Serial No. 60/080,166, filed Mar. 31, 1998 The prior applications are hereby incorporated herein by reference.

INT-CL: [07] A61 K 39/02

US-CL-ISSUED: 424/234.1; 424/130.1, 424/141.1, 424/150.1, 424/164.1, 530/387.1, 530/388.1, 530/388.2, 530/388.4, 530/387.5, 435/70.2, 435/70.21

US-CL-CURRENT: 424/234.1; 424/130.1, 424/141.1, 424/150.1, 424/164.1, 435/70.2, 435/70.21, 530/387.1, 530/387.5, 530/388.1, 530/388.2, 530/388.4

FIELD-OF-SEARCH: 530/350, 530/387.1, 530/388.1, 530/388.2, 530/388.4, 530/387.5, 424/130.1, 424/141.1, 424/150.1, 424/164.1, 435/70.2, 435/70.21

PRIOR-ART-DISCLOSED:

U.S. PATENT DOCUMENTS

Search Selected

Search ALL

Clear

PAT-NO

ISSUE-DATE

PATENTEE-NAME

US-CL

<input type="checkbox"/>	<u>5200344</u>	April 1993	Blaser et al.
<input type="checkbox"/>	<u>5470958</u>	November 1995	Blaser et al.

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
WO 95/05850	March 1995	WO	

OTHER PUBLICATIONS

Willis, WL et al, Poultry Science, Feb 1997, vol. 76(2), pp. 314-317, abstract only.*

Blankenship, LC et al, Journal of Food Protection, vol. 46(6), pp. 510-513, 1983 abstract only.*

Moran, AP et al, Mar. 1989, pp. 253-260, vol. 97(3), APMIS, Serological analysis of heat stable antigens involved in serotyping *Campylobacter jejuni* and *Campylobacter coli*.*

Yuki, N et al, Journal of neurological sciences, May 1995, vol. 130(1), pp. 112-116.*

Bolla, JM et al, Conference: *Campylobacter*, *Helicobacter* and amp; Sep. 15-19, 1997, Cape Town, South Africa, pp. 280-283, International Workshop; 9th.*

Huyet, Met al, Abstracts of the Annual Meeting Am. Soc. Microbiology, vol. 87(0), Mar. 1-6, 1987, p. 234, abstract K190.*

Mandrell, RE et al, abstract P50, p. 412, Abstracts of the Annual Meeting Am. Soc. Microbiologist, May 17-21, 1998.*

Moutinho-Fragoso et al, International Workshop of *Campylobacter*, *Helicobacter* and amp. 9th, Sep. 1997, pp. 312-316.*

Riverson, EA et al, 86th Annual Meeting of the American Society of Microbiology, vol. 86(0), pp. 422, 1986, Mar. 23-28, 1986 "A monoclonal antibody reactive against *Campyloracter jejuni* and *Campylobacter coli*.", #V-16, abstract only.*

Wong, PCK et al, Abstracts of the General Meeting of the American Society of Microbiology, vol. 95(0), May 21-25, 1995, abstract P-53, p. 391, abstract only.*

Yoshida, S et al, Am. J. Vet. Res., vol. 48(5), May 1987, pp. 801-804 (best copy possible).*

Yuki, N et al, Journal of neurological sciences, May 1995, vol. 130(1), pp. 112-116.*

Amako, K., et al., "Electron Microscopy of the Major Outer Membrane Protein of *Campylobacter jejuni*," Microbiol. Immunol. (1996) 40(10):749-754.

Bacon, D.J. Dissertation Abstracts International (Oct. 1997) 58(4):1665-B.

Bacon, D.J. et al., "Identification and Characterization of cytotoxic porin-lipopolysaccharide complex from *Campylobacter jejuni*," J. Med. Microbiol. (1999) 48:139-148.

Barroso, D. et al. Microb Ecol. Health Dis. (Oct. 1991) 4 (spec. issue):S25.

Bolla, J-M et al., "Conformational Analysis of the *Campylobacter jejuni* Porin," Journal of Bacteriology (1995) 177(15):4266-4271.

Brooks, B.W. et al., "Specificity of Monoclonal Antibodies to *Campylobacter jejuni* Lipopolysaccharide Antigens," Immunological Investigations (1998) 27(4&5):257-265.

Chalyaroj, S.C. et al., "Production of Monoclonal Antibody Specific to *Campylobacter jejuni* and Its Potential in Diagnosis of *Campylobacter* Enteritis," Asian Pacific Journal of Allergy and Immunology (1995) 13:55-61.

Chart, H. et al., "Outer Membrane Characteristics of *Campylobacter jejuni* grown in Chickens," FEMS Microbiology Letters, (Dec. 1996) 145:469-472.

Griffiths, P.L. et al., J. of Applied Bacteriology (1992) 72:467-474.

Gueerry, P. "Nonlipopolysaccharide Surface Antigens of *Campylobacter* Species," J. Infectious Diseases (Dec. 1997) 176(suppl 2):S122-S124.

Harlow, E. et al., Antibodies: A Laboratory Manual (1998) 55-133.

Huyer, M. et al., "Outer Membrane Porin Protein of *Campylobacter jejuni*," FEMS Microbiology Letters (1986) 37(3):247-250.

Kosunen, T.U. et al., "Analysis of *Campylobacter jejuni* Antigens with Monoclonal Antibodies," Journal of Clinical Microbiology (1984) 19:129-133.

Kuan, S.K.C. et al., "Production of a Monoclonal Antibody that Recognizes the Lipopolysaccharide of a *Campylobacter*-Like Organism," Microbiol. Immunol. (1992) 36(8):791-801.

Lam, K.M., "Use of 45 kDa Protein in the Detection of *Campylobacter jejuni*," Avian Pathology (1992) 21(4):643-650.

Lamoureux, M. et al., "Detection of *Campylobacter jejuni* in Food and Poultry Viscera Viscera Using Immunomagnetic Separation and Microtitre Hybridization," Journal of Applied Microbiology (1997) 83:641-651.

Lu, P. et al., "Characterization of Monoclonal Antibodies for the Rapid Detection of Foodborne *Campylobacter*," International Journal of Food Microbiology (1997) 37:87-91.

Monfort, J.D. et al., "Detection of Flagellar Antigen of *Campylobacter jejuni* and *Campylobacter coli* in Canine Faeces with an Enzyme-Linked Immunosorbent Assay (ELISA) -New Prospects for Diagnosis," Veterinary Research Communication (1994) 18(2):85-92.

Moser, I. et al., "In vitro binding of *Campylobacter jejuni*/coli outer membrane preparations to INT 407 cell Membranes," Med. Microbiol Immunol. (1992) 180(6):289-303.

Nachamkin, I. et al., "Common and Specific Epitopes of *Campylobacter* Flagellin Recognized by Monoclonal Antibodies," Infection Immunity (Aug. 1986) 52(2):438-440.

Page, W.J. et al., "Comparison of Methods Using to Separate the Inner and Outer Membranes of Cell Envelopes of *Campylobacter* spp.," Journal of General Microbiology (Nov. 1988) 134(pt11):2925-2932.

Page, W.J. et al., "Characterization of the Porins of *Campylobacter jejuni* and *Campylobacter coli* and Implications for Antibiotic Susceptibility," Antimicrobial Agents and Chemotherapy (Mar. 1989) 33(3):297-303.

Rice, B.E. et al., "Development of a Rapid and Specific Colony-Lift Immunoassay for Detection and Enumeration of *Campylobacter jejuni*, *C. coli*, and *C. lari*," Clinical and Diagnostic Laboratory Immunology (1996) 3(6):669-677.

Schroder, W. et al., "Primary Structure Analysis and Adhesion Studies on the Major Outer Membrane Protein of *Campylobacter jejuni*," FEMS Microbiology Letters (May 1997) 150(10):141-147.

Stills Jr., H.F. et al., "Utilization of Monoclonal Antibodies to Evaluate the Involvement of *Campylobacter jejuni* in Proliferative Ileitis in Syrian Hamsters (*Mesocricetus auratus*)," Infection Immunity (Sep. 1987) 55(9):2240-2246.

Warguin, I. et al., "Monoclonal IgM Antibodies to GM1 and Asialo-GM1 in Chronic Neuropathies Cross-React with *Campylobacter jejuni* Lipopolysaccharides," American Neurological Association (Jun. 1994) 35(6):698-703.

Yuki, N. et al., "Penner's Serotype 4 of *Campylobacter jejuni* Has a Lipopolysaccharide That Bears a GM1 Ganglioside Epitope as well as One That Bears a GD1a Epitope," Infection and Immunity (May 1994) 62(5):2101-2103.

Zhang, J. et al., "The *Campylobacter jejuni* Porin Timers Pack into Different Lattice Lattice Types When Reconstituted in the Presence of Lipid," Eur. J. Biochem. (1997) 244:575-579.

ART-UNIT: 1645

PRIMARY-EXAMINER: Smith; Lynette R. F.

ASSISTANT-EXAMINER: Portner; Ginny Allen

ATTY-AGENT-FIRM: Connor; Margaret A. Wai; Thanda Fado; John

ABSTRACT:

The present invention is directed to a method of producing monoclonal antibodies that are highly specific for (1) unique epitopes of *Campylobacter jejuni* (Cj) only and (2) epitopes conserved between *Campylobacter jejuni* and *Campylobacter coli* (Cc) outer membranes; to specific monoclonal antibodies made by the methods of the instant invention; and uses thereof The invention is drawn further to immunogens comprising the outer membrane complexes of Cj and Cc.

4 Claims, 34 Drawing figures

Generate Collection

Print

Search Results - Record(s) 1 through 7 of 7 returned.

- ☐ 1. 6551599. 16 Mar 01; 22 Apr 03. Monoclonal antibodies against campylobacter jejuni and campylobacter coli outer membrane antigens. Mandrell; Robert E., et al. 424/234.1; 424/130.1 424/141.1 424/150.1 424/164.1 435/70.2 435/70.21 530/387.1 530/387.5 530/388.1 530/388.2 530/388.4. A61K039/02.
- ☐ 2. 6395879. 26 Mar 99; 28 May 02. Monoclonal antibodies against Campylobacter jejuni and Campylobacter coli outer membrane antigens. Mandrell; Robert E., et al. 530/388.2; 424/164.1 435/7.32 530/388.1. G01N033/554 G01N033/569.
- ☐ 3. 6077678. 27 Jan 99; 20 Jun 00. Methods for detecting Campylobacter bacteria or antibodies to Campylobacter bacteria with an immunoassay. Pace; John Lee, et al. 435/7.1; 424/282.1 424/802 424/93.1 424/93.4 435/243 435/252.1 435/7.2 435/822 435/960 435/975. A61K045/00 C12N001/00 C12N001/12 G01N033/53.
- ☐ 4. 6057115. 16 Jun 95; 02 May 00. Process for producing GM2 specific antibodies. Ritter; Gerd, et al. 435/7.23; 435/7.32 436/543 436/547. G01N033/574 G01N033/53.
- ☐ 5. 5871731. 10 Dec 96; 16 Feb 99. Oral administration of immunoglobulin preparations for treatment of chronic pain syndrome. Sprotte; Gunter, et al. 424/130.1; 424/135.1 424/184.1 514/2 514/21 530/387.1 530/388.1 530/833. A61K039/395 A61K039/38 A61K038/00 C07K016/00.
- ☐ 6. 5854007. 24 Apr 97; 29 Dec 98. Process for producing GM1 specific antibodies. Ritter; Gerd, et al. 435/7.23; 436/547 530/387.7 530/388.4 530/388.8 530/389.5. G01N033/574 G01N033/53.
- ☐ 7. 5470958. 16 Sep 94; 28 Nov 95. Antisera against a PEB1 antigen from Campylobacter jejuni. Blaser; Martin J., et al. 530/389.5; 424/164.1 435/252.1 435/7.32 435/822. A61K035/16 A61K039/106.

Generate Collection

Print

Terms	Documents
(antibod\$ or antiser\$ or immunoglob\$ or polyclonal or poly-clonal or immune or igg or siga or iga or igm or anti-flagella or anti-flagella or anti-flagellin).ti. and L1	7

[Prev Page](#) [Next Page](#) [Go to Doc#](#)